Mexylor

Lormetazepam, the active ingredient in Mexylor, is a benzodiazepine presented as an oral formulation for oral use. It is used for short‑term treatment of insomnia in adults. GNH USA supplies Mexylor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lormetazepam acts on the central nervous system to promote sleep in patients with insomnia.

Insomnia: facilitates sleep initiation and maintenance during short‑term therapy. Sleep onset insomnia: reduces the time required to fall asleep. Sleep maintenance insomnia: decreases the number of nocturnal awakenings.

Lormetazepam may cause a range of adverse reactions, some of which are frequent while others are rare but serious.

Common Side Effects: - Drowsiness - Fatigue - Dizziness - Ataxia - Memory impairment - Headache

Serious or Rare Side Effects: - Respiratory depression - Dependence or withdrawal syndrome - Paradoxical reactions such as agitation - Severe allergic reactions (e.g., rash, angioedema) - Depression or suicidal ideation - Hepatic dysfunction

When prescribing Lormetazepam, clinicians should consider several safety measures.

Assess treatment duration: limit use to short‑term periods to avoid dependence. Avoid in severe respiratory insufficiency: risk of respiratory depression. Exercise caution in the elderly: increased fall and fracture risk. Do not combine with alcohol or other CNS depressants: additive sedation. Monitor for signs of dependence or abuse. Store at ambient temperature: keep in the original pack, protect from moisture.

Lormetazepam can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Alcohol: additive central nervous system depression. - Opioids: heightened risk of respiratory depression. - Other benzodiazepines: cumulative sedative effect.

Moderate Interactions (Monitor Closely): - SSRIs or other antidepressants: may increase sedation. - Antihistamines: additive drowsiness. - CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma concentrations of lormetazepam.